|
Aug 7
|
Theravance Biopharma Second Quarter 2024 Earnings: Misses Expectations
|
|
Aug 6
|
Theravance (TBPH) Q2 Loss Wider Than Expected, Revenues Rise Y/Y
|
|
Jul 24
|
Theravance Biopharma, Inc. (NASDAQ:TBPH): When Will It Breakeven?
|
|
Jul 22
|
Theravance Biopharma to Report Second Quarter 2024 Financial Results on August 5, 2024
|
|
Jun 26
|
Here's Why You May Invest in Theravance (TBPH) Stock Now
|
|
Jun 21
|
Wall Street Analysts Predict a 90.53% Upside in Theravance Bio (TBPH): Here's What You Should Know
|
|
May 30
|
High Insider Ownership Growth Companies On US Exchange May 2024
|
|
May 14
|
Theravance (TBPH) Q1 Earnings Top, Revenues Match Estimates
|
|
May 13
|
Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates
|
|
May 13
|
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
|
|
May 9
|
Theravance Biopharma to Participate in an Upcoming Investor Conference
|
|
Apr 29
|
Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024
|
|
Apr 15
|
BTIG Research Predicts Over 118% Rally for These 3 Stocks
|
|
Apr 15
|
Strength Seen in Theravance Bio (TBPH): Can Its 7.6% Jump Turn into More Strength?
|
|
Apr 10
|
Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024
|
|
Apr 3
|
Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue?
|
|
Mar 27
|
Why Is Theravance Bio (TBPH) Down 9% Since Last Earnings Report?
|
|
Mar 12
|
Short-Squeeze Showdown: 3 Stocks Ready to Crush the Skeptics
|
|
Jan 12
|
Down -11.17% in 4 Weeks, Here's Why Theravance Bio (TBPH) Looks Ripe for a Turnaround
|
|
Jan 5
|
Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
|